Intra-arterial thrombolysis within three hours of stroke onset in middle cerebral artery strokes
- PMID: 19225909
- DOI: 10.1007/s12028-009-9198-8
Intra-arterial thrombolysis within three hours of stroke onset in middle cerebral artery strokes
Abstract
Background and purpose: The Prolyse in Acute Cerebral Thromboembolism II (PROACT II) trial showed improved outcomes in patients with proximal middle cerebral artery (MCA) occlusions treated with intra-arterial (IA) thrombolysis within 6 h of stroke onset. We analyzed outcomes of patients with proximal MCA occlusions treated within 3 h of stroke onset in order to determine the influence of time-to-treatment on clinical and angiographic outcomes in patients receiving IA thrombolysis.
Methods: Thirty-five patients from three academic institutions with angiographically demonstrated proximal MCA occlusions were treated with IA thrombolytics within 3 h of stroke onset. Outcome measures included outcomes at 30-90 day follow-up, recanalization rates, incidence of symptomatic intracranial hemorrhage, and mortality in the first 90 days. The endpoints were compared to the IA treated and control groups of the PROACT II trial.
Results: The median admission National Institutes of Health Stroke Scale (NIHSS) score was 16 (range 4-24). The mean time to initiation of treatment was 106 min (range 10-180 min). Sixty-six percent of patients treated, had a modified Rankin Scale (mRS) score of 2 or less at 1-3 month follow-up compared to 40% in the PROACT II trial. The recanalization rate was 77% (versus 66% in PROACT II). The symptomatic intracranial hemorrhage rate was 11% (versus 10% in PROACT II) and the mortality rate was 23% (versus 25% in PROACT II).
Conclusion: Time-to-treatment is just as important in IA thrombolysis as it is in IV thrombolysis, both for improving clinical outcomes and recanalization rates as well.
Similar articles
-
Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism.JAMA. 1999 Dec 1;282(21):2003-11. doi: 10.1001/jama.282.21.2003. JAMA. 1999. PMID: 10591382 Clinical Trial.
-
Early reperfusion and clinical outcomes in patients with M2 occlusion: pooled analysis of the PROACT II, IMS, and IMS II studies.J Neurosurg. 2014 Dec;121(6):1354-8. doi: 10.3171/2014.7.JNS131430. Epub 2014 Sep 26. J Neurosurg. 2014. PMID: 25259569
-
Intra-arterial administration of microbubbles and continuous 2-MHz ultrasound insonation to enhance intra-arterial thrombolysis.J Neuroimaging. 2010 Jul;20(3):224-7. doi: 10.1111/j.1552-6569.2008.00357.x. Epub 2009 Feb 13. J Neuroimaging. 2010. PMID: 19226340
-
Excellent rates of recanalization and good functional outcome after stent-based thrombectomy for acute middle cerebral artery occlusion. Is it time for a paradigm shift?J Clin Neurosci. 2013 Sep;20(9):1219-23. doi: 10.1016/j.jocn.2012.11.011. Epub 2013 Apr 18. J Clin Neurosci. 2013. PMID: 23602573 Review.
-
Intra-arterial thrombolysis.Neurology. 2001;57(5 Suppl 2):S58-60. doi: 10.1212/wnl.57.suppl_2.s58. Neurology. 2001. PMID: 11552057 Review.
Cited by
-
Hemorrhage/contrast staining areas after mechanical intra-arterial thrombectomy in acute ischemic stroke: imaging findings and clinical significance.AJNR Am J Neuroradiol. 2012 Oct;33(9):1791-6. doi: 10.3174/ajnr.A3044. Epub 2012 Apr 26. AJNR Am J Neuroradiol. 2012. PMID: 22538076 Free PMC article. Clinical Trial.
-
Current recommendations for endovascular interventions in the treatment of ischemic stroke.Curr Atheroscler Rep. 2010 Jul;12(4):244-50. doi: 10.1007/s11883-010-0115-6. Curr Atheroscler Rep. 2010. PMID: 20461559
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources